Welcome to our dedicated page for VVY news (Ticker: VVY), a resource for investors and traders seeking the latest updates and insights on VVY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VVY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VVY's position in the market.
Vivoryon Therapeutics (Euronext Amsterdam: VVY) reported Q1 2026 results and a kidney disease pipeline update. Varoglutamstat showed statistically significant eGFR improvements in two Phase 2 studies, with pronounced effects in elderly patients with diabetes, supporting a planned Phase 2b study in stage 3b/4 DKD, subject to new funding or partnerships.
Q1 2026 R&D and G&A each were EUR 0.9 million, and net loss was EUR 1.8 million. Cash and cash equivalents were EUR 4.0 million on March 31, 2026. Vivoryon reconfirmed guidance that existing cash should fund operations into Q4 2026, while actively pursuing strategic partnering and additional financing.
Vivoryon Therapeutics (VVY), a clinical-stage company developing small molecule medicines for inflammatory and fibrotic disorders focused on kidney diseases, will publish its Q1 2026 financial results for the period ended March 31, 2026 on Thursday, June 11, 2026.
The next financial and business update conference call/webcast is planned with the H1 2026 results, anticipated in August.
Vivoryon Therapeutics (Euronext: VVY) reported full-year 2025 results and a business update on April 23, 2026. Key highlights: varoglutamstat showed consistent eGFR benefit in two Phase 2 studies; a U.S. composition-of-matter patent runs through 2044; private placement raised €5.1M; cash of €5.6M; runway into Q4 2026.
The company plans a focused Phase 2b in stage 3b/4 DKD subject to funding or partnership and continues preclinical and MOA work supporting QPCT/L inhibition.
Vivoryon Therapeutics (Euronext: VVY) will report its full year 2025 financial results and business updates on April 23, 2026. The company will host a public conference call and webcast on April 23, 2026 at 3:00 pm CEST / 9:00 am EDT.
Investors can download the report and access the live audio webcast from Vivoryon’s investor website. Telephone participation requires pre-registration to receive dial-in details; attendees are advised to join 15 minutes early.
Vivoryon Therapeutics (Euronext: VVY) announced management will attend the Van Lanschot Kempen Life Sciences Conference on April 16, 2026 in Amsterdam.
Attendee: Julia Neugebauer, PhD, COO. The participation signals management engagement with investors and analysts at the event.
Vivoryon Therapeutics (Euronext: VVY) presented new analyses at the World Congress of Nephrology (March 28, 2026) reinforcing glutaminyl cyclases as targets in diabetic kidney disease (DKD). Phase 2 data from VIVIAD and VIVA-MIND showed consistent eGFR benefits, stronger effects in elderly patients with diabetes, and supportive DKD mouse-model improvements.
The company said these translational results support further development of varoglutamstat for patients with diabetes and more advanced chronic kidney disease stages.
Vivoryon Therapeutics (Euronext: VVY) announced management will attend and present at several medical and investor conferences in early 2026. Scheduled events include 1x1s around J.P. Morgan Healthcare Conference in San Francisco on Jan 12–14, 2026, the UBS European Healthcare Conference in London on Mar 3–4, 2026, and the World Congress of Nephrology (WCN) in Yokohama on Mar 28–31, 2026. The company focuses on small‑molecule therapies for inflammatory and fibrotic kidney diseases. For investor meetings contact: IR@vivoryon.com. A link to WCN is provided for conference details.
Vivoryon Therapeutics (VVY) reported Q3 2025 results and business updates on December 4, 2025. The company highlighted new pooled analyses from its varoglutamstat Phase 2 program showing a consistent treatment effect on kidney function, with improvements of 5.3–7.7 mL/min/1.73m2/year in lower baseline eGFR percentiles, and presented VIVIAD data at ASN Kidney Week on November 6, 2025.
Corporate updates include a successful private placement raising EUR 5.1 million (3,380,500 shares at EUR 1.50) extending cash runway into Q3 2026, and a CFO transition with Marcus Irsfeld named permanent CFO in December 2025. Financials: R&D expenses down to EUR 3.7m, net loss EUR 7.6m, and cash of EUR 2.5m as of September 30, 2025.
Vivoryon Therapeutics (Euronext: VVY) will publish its Q3 2025 financial results and provide an operational update on December 4, 2025. The company will host a public conference call and live webcast at 3:00 pm CET / 9:00 am EST to discuss results and corporate developments.
Investors can access the live audio webcast on the company's investor site and join the call by pre-registering for phone dial-in details. Attendees are advised to dial in 15 minutes before the scheduled start to avoid delays.
Vivoryon Therapeutics (Euronext: VVY) presented Phase 2 kidney function and biomarker data on November 6, 2025 at ASN Kidney Week 2025. A late-breaking poster titled “Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data from VIVIAD, a Phase 2B Randomized Clinical Trial” reported that a decrease in pE-CCL2 at week 48 correlated significantly with a positive (improved) eGFR slope on an individual-patient level. Prior VIVIAD Phase 2b results also linked pE-CCL2 reduction with eGFR improvement across dose groups and in participants with and without diabetes. Vivoryon said it plans a dedicated Phase 2b in advanced diabetic kidney disease (DKD stage 3b/4), with initiation subject to additional funding or partnership.